Skip to main content
OpenTrials
Completed

NCT Number: NCT00807326

A Comparison of Three Medications to Treat Diarrhea in Adults.

A comparison of three medications to treat diarrhea in adults.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Manipal Goa Hospital, Mormugao, Goa, India

Loading trial locations.

About this study

This single (investigator) blind, randomized, 3-arm, parallel-group study design was selected to show non-inferiority of loperamide/simeticone caplets compared to chewable tablets in a heterogeneous subject population aiming at validity of results and reducing bias. The study will also compare the loperamide/simeticone combinations versus a probiotic (Saccharomyces boulardii) in the treatment of acute diarrhea in adults. Probiotics have been used for acute infectious diarrhea to reduce the duration and severity of the illness.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female at least 18 years of age
  • Acute diarrhea illness with symptoms onset within 48 hours of study entry
  • Minimum of 3 unformed stools in 24 hours before study entry
  • Most recent stool is unformed
  • Abdominal discomfort/wind (intensity mild to severe) within 4 hours of study entry
  • Women of childbearing potential must have a negative pregnancy test at screening
  • Willing to adhere to the prohibitions and restrictions specified in this protocol
  • Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion criteria

  • Requiring hospital admission, parenteral hydration or antibiotic therapy Axillary temperature >38.2°C or oral temperature >38.6°C
  • History or clinical evidence of gross blood or pus in stool in current illness
  • Signs or symptoms of orthostatic hypotension
  • Unable to take medication and fluids by mouth
  • History of chronic gastrointestinal disease, hepatic or renal insufficiency, or other significant medical condition that could be aggravated by untreated acute diarrhea
  • Immunodeficiency (e.g. those with acquired immunodeficiency syndrome [AIDS] or known human immunodeficiency virus [HIV] infection, or undergoing chemotherapy or radiotherapy)
  • Intake of antibiotics, oral antifungals, quinidine or ritonavir within 7 days, antidiarrhoeal, promotility drugs (e.g., metoclopramide, domperidone), antiflatulents (e.g., simeticone, activated charcoal) or probiotics or bismuth salts within 48 hours, or any analgesic within 6 hours prior to study entry Hypersensitivity to loperamide, yeast, or any component of study formulations
  • Pregnant or breast-feeding
  • Unable to comply with the protocol requirements and schedule
  • Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study
  • Use of opiates (as 'recreational' drugs and as painkillers)

Treatment and study plan

Loperamide/simeticone 2 mg/125 mg caplets

Drug

Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)

Other names: Imodium® Plus Caplet

Loperamide/simeticone 2 mg/125 mg chewable tablets

Drug

Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)

Other names: Imodium® Plus Chewable tablet

Probiotic Saccharomyces boulardii 250 mg capsules

Drug

Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)

Other names: Perenterol® Forte 250mg capsules

Primary outcomes

  1. Number of unformed stools

    Time frame: 0-24 hours

Secondary outcomes

  1. Number of unformed stools

    Time frame: 0-12, 12-24, 24-36, 36-48 hours

  2. Time to last unformed stool

    Time frame: Throughout duration of the study

  3. Time to complete relief of abdominal discomfort

    Time frame: Throughout duration of the study

  4. Time to complete relief of diarrhea

    Time frame: Throughout duration of the study

  5. Proportion of subjects with complete relief of diarrhea

    Time frame: 4, 8, 12, 24 and 48 hours

  6. Gas-related abdominal discomfort ratings - change from baseline at subsequent time points

    Time frame: Throughout duration of the study

  7. Proportions of subjects with complete well-being

    Time frame: at 12, 24 and 48 hours.

  8. Subject's evaluation of treatment effectiveness for overall illness relief, diarrhea relief and abdominal discomfort relief

    Time frame: Throughout duration of the study

  9. Number of loperamide/simeticone 2 mg/125 mg caplets or chewable tablets or probiotic (Saccharomyces boulardii) 250 mg capsules used during the study

    Time frame: Throughout duration of the study

  10. Frequency of complete well-being following diarrhea illness

    Time frame: at 7 days follow up

  11. Stool frequency

    Time frame: at 7 days follow up

  12. Frequency of diarrhea relapse

    Time frame: at 7 days follow up

  13. Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.

    Time frame: throughout duration of the study (+ 30 days for spontaneously-reported SAEs)

Sponsors and collaborators

Lead sponsor

McNeil AB

Industry

Registry information

Official study title

A Randomized, Parallel Group Comparison of Loperamide/Simeticone Caplet, Loperamide/Simeticone Chewable Tablet (IMODIUM® PLUS) and a Probiotic (Saccharomyces Boulardii) in the Treatment of Acute Diarrhea in Adults

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Dec 11, 2008
Registry last updated
Jul 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.